Wound closure in patients with DFU: A cost-effectiveness analysis of two cellular/tissue-derived products

Journal of Wound Care

Volumn 24, Issue 3, 2015, Pages 149-156

  Gilligan, A M ^a,b   Waycaster, C R ^a,b   Landsman, A L ^c  

^a Smith and Nephew Research Centre   (United Kingdom)

^b UNIVERSITY OF NORTH TEXAS   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cost effectiveness; Diabetic foot ulcer; Extracellular matrix; Human fibroblast derived dermal substitute

Indexed keywords

AGED; ARTIFICIAL SKIN; BANDAGE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; ECONOMICS; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST; HUMAN; MALE; MEDICAID; MEDICARE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; WOUND CLOSURE; WOUND HEALING;

AGED; AGED, 80 AND OVER; BANDAGES; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC FOOT; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; HUMANS; MALE; MEDICAID; MEDICARE; MIDDLE AGED; SKIN, ARTIFICIAL; TREATMENT OUTCOME; UNITED STATES; WOUND CLOSURE TECHNIQUES; WOUND HEALING;

EID: 84924982630     PISSN: 09690700     EISSN: 20522916     Source Type: Journal    
DOI: 10.12968/jowc.2015.24.3.149     Document Type: Article

References (40)

1. Lazarus, G. S., Cooper, D. M., Knighton, D. R., et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol 1994;130:4, 489-493.
2. Adair, H. M. Epidermal repair in chronic venous ulcers. Br J Surg 1977;64:11, 800-804.
3. Doillon, C. J., Wasserman A. J., Berg R. A., Silver F. H. Behaviour of fibroblasts and epidermal cells cultivated on analogues of extracellular matrix. Biomaterials. 1988;9:1, 91-96.
4. Grinnell, F. Fibronectin and wound healing. J Cell Biochem 1984;26:2, 107-116.
5. Haukipuro, K., Melkko, J., Risteli, L., et al. Synthesis of type I collagen in healing wounds in humans. Ann Surg 1991;213:1, 75-80.
6. Ongenae, K. C., Phillips, T. J., Park, H. Y. Level of fibronectin mRNA is markedly increased in human chronic wounds. Dermatol Surg 2000;26:5, 447-451.
7. Blakytny, R., Jude, E. The molecular biology of chronic wounds and delayed healing in diabetes. Diabet Med 2006;23:6, 594-608.
8. Hehenberger, K., Heilborn, K., Brismar, K., Hansson, A. Impaired proliferation of fibroblasts derived from chronic diabetic wounds and normal dermal fibroblasts treated with high glucose is associated with increased formation of l-lactate. Wound Repair Regen 1998;6:2, 135-141.
9. Kirsner, R. S., Warriner, R., Michela, M., et al. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol 2010;146:8, 857-862.
10. Veves, A., Falanga, V., Armstrong, D. G., et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 2001;24:2, 290-295.
11. Wieman, T. J., Smiell, J. M., Su, Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care 1998;21:5, 822-827.
12. Margolis, D. J., Kantor, J., Santanna, J., et al. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care. 2001;24:3, 483-488.
13. Landsman, A., Roukis, T. S., DeFronzo, D. J. et al. Living cells or collagen matrix: Which is more beneficial in the treatment of diabetic foot ulcers? Wounds. 2008;20:5, 111-116.
14. Steed, D. L., Attinger, C., Colaizzi, T., et al. Guidelines for the treatment of diabetic ulcers. Wound Repair Regen 2006;14:6, 680-692.
15. Brown-Etris, M., Cutshall, W., Hiles, C. A new biomaterial derived from small intestine submucosa and developed into a wound matrix device. Wounds. 2002;14:4, 150-166.
16. Badylak, S. F., Lantz, G. C., Coffey, A., Geddes, L. A. Small intestinal submucosa as a large diameter vascular graft in the dog. J Surg Res 1989;47:1, 74-80.
17. Edmonds, M. E., Foster, A. V., McColgan, M. 'Dermagraft': a new treatment for diabetic foot ulcers. Diabet Med 1997;14:12, 1010-1011.
18. Hart, C. E., Loewen-Rodriguez, A., Lessem, J. Dermagraft: Use in the treatment of chronic wounds. Adv Wound Care (New Rochelle) 2012;1:3, 138-141.
19. Niezgoda, J. A., Van Gils, C. C., Frykberg, R. G., Hodde, J. P. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18:5 Pt 1, 258-266.
20. Marston, W. A., Hanft, J., Norwood, P., Pollak, R. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. Diabetes Care 2003;26:6, 1701-1705.
21. Gentzkow, G. D., Jensen, J. L., Pollak, R. A., et al;. Improved healing of diabetic foot ulcers after grafting with a living human dermal replacement. Wounds 1999;11:3, 77-84.
22. Hanft, J. R., Surprenant, M. S. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 2002;41:5, 291-299.
23. Gentzkow, G. D., Iwasaki, S. D., Hershon, K. S. et al. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996;19:4, 350-354.
24. Pollak, R. A., Edington, E., Jensen, J. L. et al. A human dermal replacement for the treatment of diabetic foot ulcers. Wounds 1997;9:175-183.
25. Hanft, J. R., Surprenant, M. S. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg 2002;41:5, 291-299.
26. Marston WA, Hanft J, Norwood P, et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care 2003;26:6, 1701-1705.
27. Sonnenberg, F. A., Beck, J. R. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:4, 322-338.
28. Department of Health & Human Services Centers for Medicare and Medicaid Services. CMS Manuel System Pub 100-04 Medicare Claims Processing: Update of the Hospital Outpatient Prospective Payment System. 2014. www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R2845CP.pdf. (accessed 30 July 2014).
29. Dermagraft Directions For Use. Organogenesis, Inc. 2012. http://www.dermagraft.com/efficacy/ (accessed 15 May 2014).
30. Frykberg, R. G., Zgonis, T., Armstrong, D. G. et al. Diabetic foot disorders. A clinical practice guideline. (2006 revision) J Foot Ankle Surg 2006; suppl 5:S1-S66.
31. Allenet, B., Paree, F., Lebrun, T., et al. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the French context. Diabetes Metab 2000;26:2, 125-132.
32. Sheehan, P., Jones, P., Caselli, A., et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care 2003;26:6, 1879-1882.
33. Margolis, D. J., Gelfand, J. M., Hoffstad, O., Berlin, J. A. Surrogate end points for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2003;26:6, 1696-1700.
34. Margolis, D. J., Malay, D. S., Hoffstad, O. J., et al. Prevalence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006 to 2008: Data Points #1.: Agency for Healthcare Research and Quality, 2011.
35. Margolis, D. J., Malay, D. S., Hoffstad, O. J., et al. Incidence of diabetes, diabetic foot ulcer, and lower extremity amputation among Medicare beneficiaries, 2006 to 2008: Data Points #2. Agency for Healthcare Research and Quality, 2011.
36. Segal, L., John, S. The use of Dermagraft in neuropathic foot ulcers in people with diabetes: an economic analysis for Australia. Primary Intention 2002;10:2, 49-57.
37. Briggs, A., Sculpher, M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998;13:4, 397-409.
38. Welte, R., Feenstra, T., Jager, H., Leidl, R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004;22:13, 857-876.
39. Ghatnekar, O., Persson, U., Willis, M., Ödegaard, K. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomics 2001;19:7, 767-778.
40. Persson, U., Willis, M., Odegaard, K., Apelqvist, J.: The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Value Health 2000;3: suppl. 1, 39-46.